First-Time Moms In This State May Be Using Welfare for Paid Family Leave
By Dennis Thompson HealthDay Reporter
MONDAY, Jan. 13, 2025 (HealthDay news) -- Low-income single mothers appear to be using welfare as a form of paid family leave following childbirth.
Most women who enter the Temporary Assistance for Needy Families (TANF) program after childbirth are in the program for less than a year, researchers reported in a study published recently in the Journal of Marriage and Family.
These women seem to be turning to the program for short-term help as they focus on their child, researchers said.
“This study shows that TANF is working to support some mothers during this critical life course transition,” researcher David Rothwell, chair of family policy with the Oregon State University College of Health, said in a news release from the college.
For the study, researchers analyzed birth data in Oregon from 2016 and 2017, comparing it with participation in the state-run, federally-funded TANF program.
Each year, about 38,000 babies are born in Oregon. More than 40% of those births are funded by Medicaid, a number that tracks with national trends, researchers said.
About one-quarter of low-income mothers relied on TANF at any time during the two years studied, results show, with about 70% participating during the six months after birth.
About 41% of the women enrolled around the time of delivery, and then were highly likely to leave the program within six months, researchers said.
TANF is the only cash assistance program available to low-income families, researchers said. In Oregon, first-time moms with low income are eligible for TANF in the ninth month of pregnancy, and families can receive monthly assistance for up to five years.
Oregon’s TANF program tends to be more generous than others -- about 49% of poor families receive payments from the program, compared to 21% nationally, researchers said.
“In this way, the Oregon context is like an upper bound for TANF,” Rothwell said. “Some may look to this as an example of what TANF could be in their state. Or in some more restrictive states, they may look at the Oregon context and conclude, we never want our TANF to be that generous.”
Rothwell suspects that outright paid family leave would be preferable for these new mothers -- an assertion that can be measured in a future study, given that Oregon established a taxpayer-funded paid family leave program in 2023.
Oregon’s paid leave program replaces 100% of a minimum-wage worker’s wages for 14 weeks. By comparison, someone earning $540 a week would receive only $449 monthly from TANF.
“I think paid leave is more appealing than TANF for more than just the higher benefit,” Rothwell said. “While both programs place administrative burdens on applicants, I think there are fewer hurdles associated with applying for paid leave.”
“There also isn’t a stigma attached to paid leave. It seems likely that many would-be short-term TANF users will opt for paid leave now that it’s available,” Rothwell added.
Paid leave programs also might help support workforce needs, Rothwell added. For every 100 job openings in Oregon, there currently are roughly 66 available workers.
“Mothers who take Paid Leave Oregon will probably be more likely to return to work than those who take TANF,” Rothwell said.
“It’s worth noting, though, that TANF has work requirements; you must work or have a plan to work to get the benefits -- that was a big part of welfare reform in 1996,” Rothwell concluded. “But in Oregon there is a work requirement exemption of up to six months for women who give birth.”
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-01-14 06:00
Read more
- Medicare Patients Wait Average of 34 Days to See Neurologist After Referral
- FDA Approves Vtama (tapinarof) Cream for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
- Sumitomo Pharma America Announces U.S. FDA Approval of Gemtesa (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
- Little Medical Education Focuses on Justice-Involved Populations
- U.S. Seeing Sharp Rise in Norovirus Cases This December
- Bribing Kids With Holiday Gifts Popular With Parents, Poll Says
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions